机构:[1]Hongqiao International Institute of Medicine, Tongren Hospital and StateKey Laboratory of Oncogenes and Related Genes, Department of Pharmacologyand Chemical Biology, Shanghai Jiao Tong University School of Medicine(SJTU-SM), Shanghai 200025, China[2]Department of Pharmacy, Shanghai Universityof Medicine and Health Sciences, 279 Zhouzhu Road, Shanghai 201318,China[3]Department of General Surgery, Tongren Hospital, SJTU-SM,Shanghai 200336, China[4]Institute of Interdisciplinary Integrative BiomedicalResearch, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine,Shanghai 201203, China[5]Key Laboratory of Basic Pharmacology of Ministryof Education & Joint International Research Laboratory of Ethnomedicineof Ministry of Education, Zunyi Medical University, Zunyi 563003, China
Background: Harnessing the immune system to fight cancer has led to prominent clinical successes. Strategies to stimulate innate immune effectors are attracting considerable interest in cancer therapy. Here, through conjugating multivalent Fc fragments onto the surface of mesoporous silica nanoparticles (MSN), we developed a nanoparticlebased innate immune system activator (NISA) for breast cancer immunotherapy. Methods: NISA was prepared through conjugating mouse IgG3 Fc to MSN surface. Then, long-chain PEG(5000), which was used to shield Fc to confer nanoparticle colloidal stability, was linked to the MSN surface via matrix metalloprotease-2 (MMP-2)-cleavable peptide (GPLGIAGQC). The activation of multiple components of innate immune system, including complement and the innate cells (macrophages and dendritic cells) and the associated anticancer effect were investigated. Results: Fc fragments of NISA can be exposed through hydrolysis of long-chain PEG(5000) by highly expressed MMP-2 in tumor microenvironment. Then, effective stimulation and activation of multiple components of innate immune system, including complement, macrophages, and dendritic cells were obtained, leading to efficient antitumor effect in 4T1 breast cancer cells and orthotopic breast tumor model in mice. Conclusions: The antitumor potency conferred by NISA highlights the significance of stimulating multiple innate immune elements in cancer immunotherapy.
基金:
National Natural Science Foundation of China
(81602729, 81773274, and 82073379), “Shu Guang” Program of Shanghai
Education Development Foundation and Shanghai Municipal Education
Commission (16SG13), and Shanghai Science and Technology Commission
(20JC1410100).
第一作者机构:[1]Hongqiao International Institute of Medicine, Tongren Hospital and StateKey Laboratory of Oncogenes and Related Genes, Department of Pharmacologyand Chemical Biology, Shanghai Jiao Tong University School of Medicine(SJTU-SM), Shanghai 200025, China
共同第一作者:
通讯作者:
通讯机构:[1]Hongqiao International Institute of Medicine, Tongren Hospital and StateKey Laboratory of Oncogenes and Related Genes, Department of Pharmacologyand Chemical Biology, Shanghai Jiao Tong University School of Medicine(SJTU-SM), Shanghai 200025, China[5]Key Laboratory of Basic Pharmacology of Ministryof Education & Joint International Research Laboratory of Ethnomedicineof Ministry of Education, Zunyi Medical University, Zunyi 563003, China
推荐引用方式(GB/T 7714):
Xiang‑Yu Liu,Mao‑Hua Zhu,Xiao‑Yu Wang,et al.A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model[J].JOURNAL OF NANOBIOTECHNOLOGY.2022,20(1):doi:10.1186/s12951-022-01265-4.
APA:
Xiang‑Yu Liu,Mao‑Hua Zhu,Xiao‑Yu Wang,Xiao Dong,Hai‑Jun Liu...&Chao Fang.(2022).A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model.JOURNAL OF NANOBIOTECHNOLOGY,20,(1)
MLA:
Xiang‑Yu Liu,et al."A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model".JOURNAL OF NANOBIOTECHNOLOGY 20..1(2022)